Esperion to Participate in Upcoming Investor Conferences
November 08 2018 - 8:00AM
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on
developing and commercializing complementary, convenient,
cost-effective, once-daily, oral therapies for the treatment of
patients with elevated low density lipoprotein cholesterol (LDL-C),
today announced that the company will participate in
analyst-led fireside chats with investors at the following
conferences:
- Credit Suisse 27th Annual Healthcare
Conference in Phoenix on Tuesday, November 13, 2018 at
11:10 a.m. E.T.
- Stifel 2018 Healthcare Conference in New York
City on Wednesday, November 14, 2018 at 9:30 a.m. E.T.
- Jefferies London Healthcare Conference in
London on Thursday, November 15, 2018 at 5:00 a.m. E.T.
- Evercore ISI HealthCONx Conference in Boston
on Tuesday, November 27, 2018 at 7:35 a.m. E.T.
A live audio webcast of the Credit Suisse and Jefferies events
can be accessed on the investor relations section of the Esperion
website at www.esperion.com. Replay of the webcast will be
archived on the Company's website for 90 days following the
event.
Bempedoic Acid / Ezetimibe Combination Pill
Through the complementary mechanisms of action of inhibition of
cholesterol synthesis (bempedoic acid) and inhibition of
cholesterol absorption (ezetimibe), the bempedoic acid / ezetimibe
combination pill is our lead, non-statin, orally available,
once-daily, LDL-C lowering therapy. Inhibition of ATP Citrate Lyase
(ACL) by bempedoic acid reduces cholesterol biosynthesis and lowers
LDL-C by up-regulating the LDL receptor. Inhibition of Niemann-Pick
C1-Like 1 (NPC1L1) by ezetimibe results in reduced absorption of
cholesterol from the gastrointestinal tract, thereby reducing
delivery of cholesterol to the liver, which in turn upregulates the
LDL receptors. Phase 3 data demonstrated that this safe and well
tolerated combination results in a 35 percent lowering of LDL-C
when used with maximally tolerated statins, a 43 percent lowering
of LDL-C when used as a monotherapy, and a 34 percent reduction in
high sensitivity C-reactive protein (hsCRP).
Bempedoic Acid
With a targeted mechanism of action, bempedoic acid is a
first-in-class, complementary, orally available, once-daily ATP
Citrate Lyase (ACL) inhibitor that, reduces cholesterol
biosynthesis and lowers LDL-C by up-regulating the LDL receptor.
Similar to statins, bempedoic acid also reduces hsCRP, a key marker
of inflammation associated with cardiovascular disease. Completed
Phase 2 and Phase 3 studies conducted in almost 4,800 patients, and
approximately 3,100 patients treated with bempedoic acid, have
produced an additional 20 percent LDL-C lowering when used with
maximally tolerated statins, up to 30 percent LDL-C lowering as
monotherapy, 35 percent LDL-C lowering in combination with
ezetimibe when used with maximally tolerated statins, and up to 48
percent LDL-C lowering in combination with ezetimibe as
monotherapy.
The effect of bempedoic acid on cardiovascular morbidity and
mortality has not yet been determined. The company initiated a
global cardiovascular outcomes trial (CVOT) to assess the effects
of bempedoic acid on the occurrence of major cardiovascular events
in patients with, or at high risk for, cardiovascular disease (CVD)
who are only able to tolerate less than the lowest approved daily
starting dose of a statin and considered "statin intolerant." The
CVOT — known as Cholesterol Lowering via Bempedoic Acid,
an ACL-inhibiting Regimen (CLEAR) Outcomes — is an
event-driven, global, randomized, double-blind, placebo-controlled
study expected to enroll approximately 12,600 patients with
hypercholesterolemia and high CVD risk at over 1,000 sites in
approximately 30 countries.
Esperion's Commitment to Patients with
Hypercholesterolemia
High levels of LDL-C can lead to a build-up of fat and
cholesterol in and on artery walls (known as atherosclerosis),
potentially leading to cardiovascular events, including heart
attack or stroke. In the U.S., 78 million people, or more than 20
percent of the population, have elevated LDL-C; an additional 73
million people in Europe and 30 million people
in Japan also live with elevated LDL-C. There are
approximately 13 million people in the U.S. with atherosclerotic
cardiovascular disease (ASCVD) who live with elevated levels of
LDL-C despite taking maximally-tolerated lipid-modifying therapy —
including individuals considered statin intolerant — leaving them
at high risk for cardiovascular events. More than 6 million
patients with ASCVD and/or HeFH on maximally tolerated statins
require less than 30 percent additional LDL-C lowering to achieve
treatment goals.
Esperion's mission as the Lipid Management Company is
to deliver once-daily, oral therapies that complement existing oral
drugs to provide the additional LDL-C lowering that these patients
need.
The Lipid Management Company
Esperion is the Lipid Management Company passionately
committed to developing and commercializing convenient,
complementary, cost-effective, once-daily, oral therapies for the
treatment of patients with elevated LDL-C. Through scientific and
clinical excellence, and a deep understanding of cholesterol
biology, the experienced Lipid Management Team at Esperion is
committed to developing new LDL-C lowering therapies that will make
a substantial impact on reducing global cardiovascular disease; the
leading cause of death around the world. Bempedoic acid and the
company's lead product candidate, the bempedoic acid / ezetimibe
combination pill, are targeted therapies that have been shown to
significantly lower elevated LDL-C levels in patients with
hypercholesterolemia, including patients inadequately treated with
current lipid-modifying therapies. For more information, please
visit www.esperion.com and follow us on Twitter
at https://twitter.com/EsperionInc.
Investor Contact: Alex Schwartz Esperion
734-249-3386 aschwartz@esperion.com
Media Contact: Elliot Fox W2O Group 212-257-6724
efox@w2ogroup.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2023 to Apr 2024